Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01746134 · ClinicalTrials.gov registry record

The Management of Schizophrenia in Clinical Practice (MOSAIC)

A clinical trial of Schizophrenia, sponsored by Genentech.

Completed
Registry status
557
Enrollment target
20
Study locations

NCT01746134: Completed study of Schizophrenia, sponsored by Genentech.

NCT01746134 is a study of Schizophrenia that has completed, run by Genentech. The registered enrollment target is 557 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (157% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01746134, a study of Schizophrenia, has completed, sponsored by Genentech.

COMPLETED
Registry status
557 participants
Enrollment target
20
Study locations

Study Summary

This study is a disease-based registry designed to follow patients with a DSM-IV-TR (Diagnostic and Statistic Manual of Mental Disorders, Text Revision) diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder treated in usual care settings for up to 5 years. The registry seeks to describe the course of disease in schizophrenia, including cognitive function and negative symptoms, its treatment, and its burden of disease for participants, caregivers, clinicians, and society as a whole.

Conditions Studied

Schizophrenia

Study Locations (20)

Florida

  • - Chicago
  • - Gainesville
  • - Gainesville
  • - Gainesville
  • - Jacksonville
  • - Lake City
  • - Miami
  • - Miami

California

  • - Granada Hills
  • - Los Angeles
  • - Santa Monica

Iowa

  • - Iowa City
  • - Iowa City
  • - Iowa City

Connecticut

  • - Cedar Rapids
  • - New Haven

Minnesota

  • - Minneapolis
  • - Saint Paul

Illinois

  • - Chicago

Massachusetts

  • - Belmont

Trial Details

FieldValue
Enrollment Target 557 participants
Start Date 2012-12
Est. Completion 2014-05
Genentech

332 total trials

What the finished NCT01746134 record still lists

NCT01746134 is an observational study that tracks outcomes without assigning an intervention. The registered 557 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (157% higher).

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.

NCT01746134 names 20 study sites across 7 states, led by Florida, California, Iowa.

Frequently Asked Questions

What is clinical trial NCT01746134 about?

NCT01746134 is a clinical study titled "The Management of Schizophrenia in Clinical Practice (MOSAIC)". This study is a disease-based registry designed to follow patients with a DSM-IV-TR (Diagnostic and Statistic Manual of Mental Disorders, Text Revision) diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder treated in usual care settings for up to 5 years. The registry s...

What is the current status of trial NCT01746134?

This trial is currently completed. The enrollment target is 557 participants. The study started on 2012-12. Estimated completion is 2014-05.

What conditions does trial NCT01746134 study?

This clinical trial studies the following conditions: Schizophrenia.

Who is sponsoring clinical trial NCT01746134?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01746134 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01746134's enrollment target sits among peer trials

557 35th of 315 higher than 281 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05708885 · 557 participants · NA

    Striated Esophageal Motor Function Modulation in Health and Disease

  • NCT07173751 · 558 participants · Phase 3

    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  • NCT06074588 · 556 participants · Phase 3

    Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

  • NCT06693622 · 556 participants

    Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01746134, the US trial registry maintained by the National Library of Medicine. NCT01746134 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.